OncoMatch/Clinical Trials/NCT07473167
Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
Is NCT07473167 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies TC011 for relapsed large b-cell lymphoma.
Treatment: TC011 — This is a multi-center, phase I/II study to determine the safety and efficacy of TC011(CD19 Targeted CAR-T) in adult patients with relapsed or refractory large B-cell non -hodgkin lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic chemotherapy
Relapsed/refractory after ≥2 prior lines of systemic chemotherapy
Cannot have received: anti-CD19 agent
Prior therapies such as anti-CD19 agents
Cannot have received: adoptive T-cell therapy
Prior therapies such as ... adoptive T-cell therapy
Cannot have received: gene therapy
Prior therapies such as ... gene therapy
Cannot have received: allogeneic HSCT
Prior therapies such as ... allogeneic HSCT
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Cardiac function
LVEF ≥40%; significant cardiac disease within 6 months [excluded]
Adequate organ, and pulmonary function; LVEF ≥40%; Significant cardiac disease within 6 months [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify